Agios Pharmaceuticals (MEX:AGIO) Total Liabilities: MXN1,368 Mil (As of Mar. 2026)

What is Agios Pharmaceuticals Total Liabilities?

Agios Pharmaceuticals MEX:AGIO 44 Total Liabilities is MXN1,368 Mil as of Mar. 2026. GuruFocus rates MEX:AGIO with a GF Score™ of 44/100 and a GF Value™ of MXN2,772.90. The stock has 3 warning signs investors should review.

Agios Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was MXN1,368 Mil.

Agios Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 (MXN1,859.64 Mil) to Dec. 2025 (MXN1,874.59 Mil) but then declined from Dec. 2025 (MXN1,874.59 Mil) to Mar. 2026 (MXN1,368.23 Mil).

Agios Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (MXN2,140.44 Mil) to Dec. 2024 (MXN2,549.46 Mil) but then declined from Dec. 2024 (MXN2,549.46 Mil) to Dec. 2025 (MXN1,874.59 Mil).

Agios Pharmaceuticals Total Liabilities Related Terms

Agios Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Total Liabilities Chart

Agios Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

2,990.14

2,688.58

2,140.44

2,549.46

1,874.59

Agios Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															1,820.58	1,914.59	1,859.64	1,874.59	1,368.23

44GF Score

Agios Pharmaceuticals Inc MEX:AGIO

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Agios Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Agios Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1480.177	+	(392.794	+	1.62
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,875

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	23357.444	-	21482.853
	=	1,875

Agios Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1061.134	+	(305.474	+	1.623
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,368

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	21368.569	-	20000.338
	=	1,368

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of MXN1,368 Mil mean?

Agios Pharmaceuticals (MEX:AGIO) has a Total Liabilities of MXN1,368 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Agios Pharmaceuticals and its competitors.

Is Agios Pharmaceuticals' Total Liabilities too high?

Agios Pharmaceuticals' current Total Liabilities is MXN1,368 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.

How does Agios Pharmaceuticals' Total Liabilities compare to ABCL and KOD?

Agios Pharmaceuticals' Total Liabilities of MXN1,368 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Total Liabilities is MXN1,368 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Agios Pharmaceuticals stock overvalued right now?

Agios Pharmaceuticals (MEX:AGIO) has a current Total Liabilities of MXN1,368 Mil. The stock's GF Value™ is MXN2,772.90, compared to a current price of MXN1,222.00 — trading 55.9% below its estimated fair value. The current Total Liabilities is MXN1,368 Mil. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Agios Pharmaceuticals (MEX:AGIO), the current Total Liabilities is MXN1,368 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (MEX:AGIO) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of MXN1,222.00 is trading 55.9% below its estimated GF Value™ of MXN2,772.90.

Key valuation signals for MEX:AGIO:

Total Liabilities: MXN1,368 Mil
GF Value™: MXN2,772.90 vs. price of MXN1,222.00 (55.9% below fair value)
GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the MEX:AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ABCL KOD IMNM AUPH NTLA MLYS OCUL NKTR VCEL NRIX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges AGIO:USA 0HB0:UK 8AP:Germany

Address 88 Sidney Street, Cambridge, MA, USA, 02139

Website https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

44GF Score

Get the complete analysis for MEX:AGIO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,222.00

Price

MXN2,772.90

GF Value

View MEX:AGIO Analysis

See Total Liabilities data for all stocks →